Important Safety Information *Please note Rybelsus can be prescribed for Diabetics only* RYBELSUS may cause serious side effects, including: Possible thyroid tumors, including cancer
This guidance aims to help cardiologists and primary care providers navigate when and how to prescribe these increasingly common medications for patients struggling with obesity, diabetes or other cardiometabolic conditions
Wharton, Lingvay S, Bogdanski I, Vale P, RDd, Jacob S, et al
How GLP-1 agonists drive weight loss Appetite control GLP-1s mimic hormones that signal fullness to the brain, reducing hunger and curbing cravings Slower digestion GLP-1 agonists slow gastric emptying, helping patients feel fuller longer, and preventing overeating Improved insulin sensitivity Originally developed for diabetes care, GLP-1 medications improve how the body processes insulin Sustainable weight loss Through reduced appetite and better metabolism, patients achieve steady, meaningful weight loss Long-term benefits GLP-1 agonists not only aid weight loss but can also improve heart health and reduce diabetes risk How GLP-1 agonists drive weight loss Ongoing shortages of popular GLP-1 medications like Ozempic and Mounjaro have left many patients without the treatment they need, interrupting their progress just when consistency matters most
Interventions include adjusting treatment plans accordingly as further research continues to understand possible interactions between both drugs
What to read next
.png)
